Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort - Poll - MDSpire

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • By

  • Augustin Boudry

  • Laurène Fenwarth

  • Raphaël Itzykson

  • Thorsten Braun

  • Lionel Adès

  • Élise Fournier

  • Céline Berthon

  • Delphine Lebon

  • Stéphane De Botton

  • Régis Peffault de Latour

  • Cécile Pautas

  • Hervé Dombret

  • Emmanuel Raffoux

  • Claude Gardin

  • Karine Celli-Lebras

  • Claude Preudhomme

  • Nicolas Duployez

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

  • by Augustin Boudry, Laurène Fenwarth, Raphaël Itzykson, Thorsten Braun, Lionel Adès, Élise Fournier, Céline Berthon, Delphine Lebon, Stéphane De Botton, Régis Peffault de Latour, Cécile Pautas, Hervé Dombret, Emmanuel Raffoux, Claude Gardin, Karine Celli-Lebras, Claude Preudhomme, Nicolas Duployez

  • May 28, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report